Shares of Concert Pharmaceuticals Inc. (NASDAQ:CNCE) traded down 1.2% during trading on Friday . The stock traded as low as $9.54 and last traded at $9.59, with a volume of 62,702 shares. The stock had previously closed at $9.71.

Several analysts have recently commented on the company. Brean Capital restated a “buy” rating on shares of Concert Pharmaceuticals in a report on Tuesday, May 24th. Zacks Investment Research upgraded Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, May 17th. Finally, Stifel Nicolaus initiated coverage on Concert Pharmaceuticals in a report on Friday, July 1st. They issued a “buy” rating and a $23.00 price target on the stock. Two research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $26.43.

The company’s market cap is $215.16 million. The firm’s 50-day moving average is $11.22 and its 200-day moving average is $12.42.

Concert Pharmaceuticals (NASDAQ:CNCE) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.60) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.63) by $0.03. On average, equities research analysts expect that Concert Pharmaceuticals Inc. will post ($2.51) EPS for the current fiscal year.

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.